US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gyre Therapeutics

7.42

+0.04000.54%

Post-market: 7.440.0200+0.27%18:08 EDT

Volume:1.05M

Turnover:7.80M

Market Cap:712.17M

PE:154.34

High:7.60

Open:7.38

Low:7.20

Close:7.38

Loading ...

Overview Company News Filings

Gyre Therapeutics - to Seek Accelerated Approval for Hydronidone in Chb Fibrosis, New Drug Application Submission to Nmpa Expected in Q3

THOMSON REUTERS

President and Director Songjiang Ma Reports Disposal of Common Shares of Gyre Therapeutics Inc

Gyre Therapeutics Inc. President and Director Ma Songjiang Reports Disposal of Common Shares

Gyre Therapeutics Reports Q1 2025 Financial Results

Gyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Gyre Therapeutics Q1 Sales $22.06M Miss $28.70M Estimate

Gyre Therapeutics -Reaffirming 2025 REV Guidance of $118 Mln to $128 Mln

THOMSON REUTERS

Gyre Therapeutics Q1 Pretax Profit USD 4.635 Million

THOMSON REUTERS

Gyre Therapeutics Inc FY2025 REV View $126.5 Mln -- Lseg Ibes Data

THOMSON REUTERS

Gyre Therapeutics Inc expected to post earnings of 3 cents a share - Earnings Preview

Gyre Therapeutics Says China's NMPA Approves Pirfenidone Trial in Lung Injury

MT Newswires Live

Gyre Therapeutics announces NMPA approval for trial on pirfenidone

BRIEF-Gyre Therapeutics Announces NMPA Approval For Clinical Trial Evaluating Pirfenidone Capsules In Oncology-Related Pulmonary Complications

Gyre Therapeutics Announces Nmpa Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

THOMSON REUTERS

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings

Simply Wall St.

Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Gyre Therapeutics Reports Strong Turnaround in 2024 Earnings

Stock Track | Gyre Therapeutics Soars 7.12% Pre-Market on Profitability Turn and Revenue Beat

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GYRE/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","market":"US","secType":"STK","nameCN":"Gyre Therapeutics","latestPrice":7.42,"timestamp":1751054400000,"preClose":7.38,"halted":0,"volume":1052009,"hourTrading":{"tag":"盘后","latestPrice":7.44,"preClose":7.42,"latestTime":"18:08 EDT","volume":397817,"amount":2951769.223362,"timestamp":1751062080619},"delay":0,"floatShares":25607700,"shares":95979800,"eps":0.048077,"marketStatus":"Market Closed","change":0.04,"latestTime":"06-27 16:00:00 EDT","open":7.38,"high":7.5973,"low":7.2,"amount":7800734.472550601,"amplitude":0.053835,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.048077,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":7.38,"postHourTrading":{"tag":"盘后","latestPrice":7.44,"preClose":7.42,"latestTime":"18:08 EDT","volume":397817,"amount":2951769.223362,"timestamp":1751062080619},"volumeRatio":5.623090823505809,"impliedVol":0.938,"impliedVolPercentile":0.7273},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","floatShares":25607700,"roa":"5.18%","roe":"12.12%","lyrEps":0.142017,"volumeRatio":5.623090823505809,"shares":95979800,"dividePrice":0,"high":7.5973,"amplitude":0.053835,"preClose":7.38,"low":7.2,"week52Low":6.11,"pbRate":"10.45","psRate":"7.08","week52High":19,"institutionHeld":0.0832,"latestPrice":7.42,"eps":0.048077,"divideRate":0,"volume":1052009,"delay":0,"ttmEps":0.048077,"open":7.38,"prevYearClose":12.1,"prevWeekClose":8.07,"prevMonthClose":9.07,"prevQuarterClose":7.72,"fiveDayClose":8.07,"twentyDayClose":9.46,"sixtyDayClose":6.41},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GYRE\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2537192420","title":"Gyre Therapeutics - to Seek Accelerated Approval for Hydronidone in Chb Fibrosis, New Drug Application Submission to Nmpa Expected in Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2537192420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537192420?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:01","pubTimestamp":1747944060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUA4WSMW5:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2537628238","title":"President and Director Songjiang Ma Reports Disposal of Common Shares of Gyre Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2537628238","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537628238?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:01","pubTimestamp":1747771309,"startTime":"0","endTime":"0","summary":"Songjiang Ma, the President and a Director of Gyre Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL2M7R3h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2535002725","title":"Gyre Therapeutics Inc. President and Director Ma Songjiang Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2535002725","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535002725?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:05","pubTimestamp":1747253113,"startTime":"0","endTime":"0","summary":"Songjiang Ma, the President and Director of Gyre Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL3S91rm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2534413042","title":"Gyre Therapeutics Reports Q1 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534413042","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534413042?lang=en_us&edition=fundamental","pubTime":"2025-05-10 12:19","pubTimestamp":1746850750,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc ( ($GYRE) ) has released its Q1 earnings. Here is a breakdown of the information Gyre Therapeutics Inc presented to its inves...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-reports-q1-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-reports-q1-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2534072601","title":"Gyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2534072601","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534072601?lang=en_us&edition=fundamental","pubTime":"2025-05-09 19:19","pubTimestamp":1746789568,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryGyre Therapeutics Inc GYRE.OQ reported quarterly adjusted earnings of 3 cents per share for the quarter ended Mar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nL8N3RH1AF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE"],"gpt_icon":0},{"id":"2534108380","title":"Gyre Therapeutics Q1 Sales $22.06M Miss $28.70M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2534108380","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534108380?lang=en_us&edition=fundamental","pubTime":"2025-05-09 18:12","pubTimestamp":1746785540,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (NASDAQ:GYRE) reported quarterly sales of $22.06 million which missed the analyst consensus estimate of $28.70 million by 23.14 percent.  This is a 18.82 percent decrease over sales of $27.17 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45312741/gyre-therapeutics-q1-sales-22-06m-miss-28-70m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE"],"gpt_icon":0},{"id":"2534417098","title":"Gyre Therapeutics -Reaffirming 2025 REV Guidance of $118 Mln to $128 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2534417098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534417098?lang=en_us&edition=fundamental","pubTime":"2025-05-09 18:00","pubTimestamp":1746784800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nPLX229E34:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2534177613","title":"Gyre Therapeutics Q1 Pretax Profit USD 4.635 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534177613?lang=en_us&edition=fundamental","pubTime":"2025-05-09 18:00","pubTimestamp":1746784800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nPLX229E34:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2534170989","title":"Gyre Therapeutics Inc  FY2025 REV View $126.5 Mln -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2534170989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534170989?lang=en_us&edition=fundamental","pubTime":"2025-05-09 18:00","pubTimestamp":1746784800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nPLX229E34:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2533588469","title":"Gyre Therapeutics Inc  expected to post earnings of 3 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533588469","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533588469?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:17","pubTimestamp":1746443825,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc  expected to post earnings of3cents a share - Earnings Preview Gyre Therapeutics Inc GYRE.OQ GYRE.O is expected to report resultson May 7 (estimated) for the period ending March ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD0M7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE"],"gpt_icon":0},{"id":"2523777940","title":"Gyre Therapeutics Says China's NMPA Approves Pirfenidone Trial in Lung Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2523777940","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523777940?lang=en_us&edition=fundamental","pubTime":"2025-03-31 22:06","pubTimestamp":1743430008,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics  said Monday that China's National Medical Products Administration approved its application to conduct a clinical trial evaluating pirfenidone capsules for radiation-induced lung injury, with or without immune-related pneumonitis.The company said it expects to start the phase 2/3 trial to assess dosing and efficacy in H2 2025 at oncology and academic centers in China.Shares of the company were down 1.8% in recent Monday trading.Price: 8.95, Change: -0.16, Percent Change: -1.76","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2523910247","title":"Gyre Therapeutics announces NMPA approval for trial on pirfenidone","url":"https://stock-news.laohu8.com/highlight/detail?id=2523910247","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523910247?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:20","pubTimestamp":1743420029,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (GYRE) announced that the National Medical Products Administration, NMPA, of the People’s Republic of China, PRC, has approved it...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-nmpa-approval-for-trial-on-pirfenidone?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-nmpa-approval-for-trial-on-pirfenidone?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2523891708","title":"BRIEF-Gyre Therapeutics Announces NMPA Approval For Clinical Trial Evaluating Pirfenidone Capsules In Oncology-Related Pulmonary Complications","url":"https://stock-news.laohu8.com/highlight/detail?id=2523891708","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523891708?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:14","pubTimestamp":1743419692,"startTime":"0","endTime":"0","summary":"BRIEF-Gyre Therapeutics Announces NMPA Approval For Clinical Trial Evaluating Pirfenidone Capsules In Oncology-Related Pulmonary ComplicationsMarch 31 (Reuters) - Gyre Therapeutics Inc GYRE.O:GYRE THE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2523120369","title":"Gyre Therapeutics Announces Nmpa Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications","url":"https://stock-news.laohu8.com/highlight/detail?id=2523120369","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523120369?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:02","pubTimestamp":1743418979,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2523917982","title":"Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917982","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917982?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March  31, 2025  (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the Nat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052154/0/en/Gyre-Therapeutics-Announces-NMPA-Approval-for-Clinical-Trial-Evaluating-Pirfenidone-Capsules-in-Oncology-Related-Pulmonary-Complications.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2522539564","title":"We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539564","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539564?lang=en_us&edition=fundamental","pubTime":"2025-03-28 02:40","pubTimestamp":1743100810,"startTime":"0","endTime":"0","summary":"The stock price didn't jump after Gyre Therapeutics, Inc.  posted decent earnings last week. We did some digging and believe investors may be worried about some underlying factors in the report.We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqCM:GYRE Earnings and Revenue History March 27th 2025. To understand the value of a company's earnings growth, it is imperative to consider any dilution of shareholders' interests. In fact, Gyre Therapeutics increased the number of shares on issue by 9.7% over the last twelve months by issuing new shares. As a result, its net income is now split between a greater number of shares. Per share metrics like EPS help us understand how much actual shareholders are benefitting from the company's profits, while the net income level gives us a better view of the company's absolute size. Check out Gyre Therapeutics' historical EPS growth by clicking on this link.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/think-aware-concerning-factors-gyre-184010501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","GYRE",".IXIC","AWRE"],"gpt_icon":0},{"id":"2522379864","title":"Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351","url":"https://stock-news.laohu8.com/highlight/detail?id=2522379864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522379864?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:20","pubTimestamp":1743074411,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (GYRE) announced the publication of the manuscript titled “Hydronidone for the Treatment of Liver Fibrosis Associated with Chroni...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-publication-of-protocol-for-phase-3-trial-on-f351?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-publication-of-protocol-for-phase-3-trial-on-f351?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2522375122","title":"Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375122","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375122?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 27, 2025  -- Gyre Therapeutics  , an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced the publication of the manuscript titled “Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B: Protocol for a Phase 3 Randomized Trial” in theJournal of Clinical and Translational Hepatology.This publication details the full protocol for the pivotal Phase 3 trial to support the use of hydronidone in Chinese patients with liver fibrosis associated with chronic hepatitis B . The published protocol outlines patient inclusion criteria, randomization and blinding processes, key assessments, and the statistical analysis plan.The randomized, double-blind, placebo-controlled, multicenter Phase 3 trial  completed the enrollment of 248 patients across 44 clinical research hospitals in the People’s Republic of China  in October 2024. Patients were randomized 1:1 to receive either F351","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gyre-therapeutics-announces-publication-protocol-110000523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GYRE","CHB","BK4139"],"gpt_icon":0},{"id":"2521444293","title":"Gyre Therapeutics Reports Strong Turnaround in 2024 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2521444293","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521444293?lang=en_us&edition=fundamental","pubTime":"2025-03-21 12:08","pubTimestamp":1742530102,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc ( ($GYRE) ) has released its Q4 earnings. Here is a breakdown of the information Gyre Therapeutics Inc presented to its inves...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-reports-strong-turnaround-in-2024-earnings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-reports-strong-turnaround-in-2024-earnings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE"],"gpt_icon":0},{"id":"1186044367","title":"Stock Track | Gyre Therapeutics Soars 7.12% Pre-Market on Profitability Turn and Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1186044367","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186044367?lang=en_us&edition=fundamental","pubTime":"2025-03-19 21:32","pubTimestamp":1742391146,"startTime":"0","endTime":"0","summary":"Shares of Gyre Therapeutics  are soaring 7.12% in pre-market trading on Wednesday following the release of its Full Year 2024 financial results. The biotechnology company has shown significant improvement in its financial performance, turning profitable despite a slight decline in revenue.Gyre Therapeutics reported revenue of $105.8 million for the full year 2024, down 6.8% from the previous year but beating analyst estimates by 4.3%. The company achieved profitability with a net income of $12.1","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GYRE"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":75,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-09","symbol":"GYRE","fiscalQuarterEnding":"2025/03","expectedEps":0.03,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"pre","actualEps":0},{"market":"US","date":"2025-03-17","symbol":"GYRE","fiscalQuarterEnding":"2024/12","expectedEps":0.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"post","actualEps":0.01},{"date":"2025-02-18","symbol":"GYRE","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739869200000,"name":null,"time":"Pre-Market","dateTimestamp":1739854800000,"actualEps":null},{"market":"US","date":"2024-11-13","symbol":"GYRE","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":0.02},{"market":"US","date":"2024-08-13","symbol":"GYRE","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"pre","actualEps":0.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741752000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GYRE","date":"2025-06-27","current":92.269436,"percent":0.887372,"low":-11548.718266,"twenty":-26.976012,"median":-11.969641,"eighty":62.92987,"high":139.727206,"avg":-1155.549062,"sd":3094.591864,"marketCap":669045678},"quantilePoints":[{"date":"2024-04-05","current":-15.607876,"twenty":-15.830217,"median":-15.617068,"eighty":-15.398378,"marketCap":1450486717},{"date":"2024-04-12","current":-31.76291,"twenty":-32.589325,"median":-21.429161,"eighty":-15.61523,"marketCap":1405212396},{"date":"2024-04-19","current":-29.754799,"twenty":-32.477335,"median":-30.585076,"eighty":-15.742078,"marketCap":1316372220},{"date":"2024-04-26","current":-31.531205,"twenty":-31.948274,"median":-30.797472,"eighty":-16.000876,"marketCap":1394961607},{"date":"2024-05-03","current":-27.239192,"twenty":-31.948274,"median":-30.778163,"eighty":-24.631989,"marketCap":1205080075},{"date":"2024-05-10","current":-14.851474,"twenty":-31.774495,"median":-30.223912,"eighty":-24.631989,"marketCap":1301657414},{"date":"2024-05-17","current":-14.909982,"twenty":-31.744918,"median":-29.754799,"eighty":-15.561911,"marketCap":1306785414},{"date":"2024-05-24","current":-12.302842,"twenty":-31.573048,"median":-28.630129,"eighty":-14.89828,"marketCap":1078282562},{"date":"2024-05-31","current":-8605.737804,"twenty":-32.075712,"median":-29.501562,"eighty":-15.108912,"marketCap":890160307},{"date":"2024-06-07","current":-8895.075775,"twenty":-32.90985,"median":-30.136978,"eighty":-15.311743,"marketCap":920088848},{"date":"2024-06-14","current":-9126.546144,"twenty":-8519.763095,"median":-30.585076,"eighty":-15.366351,"marketCap":944031680},{"date":"2024-06-21","current":-8961.210165,"twenty":-8885.155616,"median":-30.816781,"eighty":-15.424018,"marketCap":926929657},{"date":"2024-06-28","current":-8175.864257,"twenty":-8865.315298,"median":-30.894016,"eighty":-15.515947,"marketCap":845695047},{"date":"2024-07-05","current":-9688.68848,"twenty":-8961.210165,"median":-31.531205,"eighty":-15.611553,"marketCap":1002178559},{"date":"2024-07-12","current":-10424.433593,"twenty":-9151.346542,"median":-31.791873,"eighty":-15.679573,"marketCap":1078282562},{"date":"2024-07-15","current":-11094.044316,"twenty":-9210.867496,"median":-31.820836,"eighty":-15.710825,"marketCap":1147545756},{"date":"2024-08-02","current":-11548.718266,"twenty":-9298.495565,"median":-32.139431,"eighty":-15.742078,"marketCap":1194576320},{"date":"2024-08-09","current":-8374.267436,"twenty":-9189.373818,"median":-32.728348,"eighty":-16.000876,"marketCap":866217475},{"date":"2024-08-16","current":-10.635127,"twenty":-9134.812943,"median":-32.641458,"eighty":-15.61523,"marketCap":914301855},{"date":"2024-08-23","current":-11.421808,"twenty":-9126.546144,"median":-31.820836,"eighty":-15.175222,"marketCap":981932798},{"date":"2024-08-30","current":-13.672312,"twenty":-9020.73112,"median":-31.635813,"eighty":-14.375603,"marketCap":1175408659},{"date":"2024-09-06","current":-11.770337,"twenty":-8974.437045,"median":-30.942288,"eighty":-13.816505,"marketCap":1011895874},{"date":"2024-09-13","current":-14.920484,"twenty":-8961.210165,"median":-30.778163,"eighty":-13.696211,"marketCap":1282714046},{"date":"2024-09-20","current":-15.572509,"twenty":-8941.369845,"median":-30.223912,"eighty":-13.816505,"marketCap":1338768556},{"date":"2024-09-27","current":-13.909847,"twenty":-8923.182886,"median":-29.754799,"eighty":-13.90034,"marketCap":1195829555},{"date":"2024-10-04","current":-13.312158,"twenty":-8919.876167,"median":-28.630129,"eighty":-13.654308,"marketCap":1144446254},{"date":"2024-10-11","current":-12.327984,"twenty":-8904.995932,"median":-26.800559,"eighty":-13.325198,"marketCap":1059836795},{"date":"2024-10-18","current":-15.235629,"twenty":-8865.315298,"median":-15.915547,"eighty":-13.300875,"marketCap":1309807059},{"date":"2024-10-25","current":-15.300832,"twenty":-8830.594739,"median":-15.607876,"eighty":-13.325198,"marketCap":1315412510},{"date":"2024-10-31","current":-15.985457,"twenty":-8804.140979,"median":-15.617068,"eighty":-13.405529,"marketCap":1374269746},{"date":"2024-11-08","current":-16.365804,"twenty":-8779.340581,"median":-15.748988,"eighty":-13.558712,"marketCap":1406968211},{"date":"2024-11-15","current":-13.372591,"twenty":-8709.89947,"median":-15.77333,"eighty":-13.558712,"marketCap":1187780244},{"date":"2024-11-22","current":-11.353175,"twenty":-8602.431085,"median":-15.627389,"eighty":-13.295234,"marketCap":1008411696},{"date":"2024-11-29","current":-12.087508,"twenty":-8556.137012,"median":-15.590193,"eighty":-13.126615,"marketCap":1073636622},{"date":"2024-12-06","current":-10.111572,"twenty":-8387.494312,"median":-15.378053,"eighty":-12.781935,"marketCap":898130076},{"date":"2024-12-13","current":-9.449706,"twenty":-8374.267436,"median":-15.329691,"eighty":-12.475931,"marketCap":839341820},{"date":"2024-12-20","current":-10.299987,"twenty":-8344.506959,"median":-15.279098,"eighty":-12.329976,"marketCap":914865419},{"date":"2024-12-27","current":-12.686569,"twenty":-8225.465052,"median":-15.246496,"eighty":-12.302842,"marketCap":1126846431},{"date":"2025-01-03","current":-11.594732,"twenty":-8192.397854,"median":-15.235629,"eighty":-12.152426,"marketCap":1029867264},{"date":"2025-01-10","current":-9.29511,"twenty":-8179.170976,"median":-15.105225,"eighty":-11.98162,"marketCap":825610256},{"date":"2025-01-17","current":-10.435259,"twenty":-3290.168076,"median":-14.953086,"eighty":-11.68749,"marketCap":926880537},{"date":"2025-01-24","current":-10.242013,"twenty":-32.95233,"median":-14.893499,"eighty":-11.536758,"marketCap":909716083},{"date":"2025-01-31","current":-11.111618,"twenty":-32.786274,"median":-14.681409,"eighty":-11.380628,"marketCap":986956128},{"date":"2025-02-07","current":-12.319402,"twenty":-32.658836,"median":-14.539395,"eighty":-11.347378,"marketCap":1094233968},{"date":"2025-02-14","current":-11.382162,"twenty":-32.515952,"median":-14.451664,"eighty":-11.279742,"marketCap":1010986364},{"date":"2025-02-21","current":-12.135819,"twenty":-32.330588,"median":-14.072853,"eighty":-11.345445,"marketCap":1077927736},{"date":"2025-02-28","current":-10.90871,"twenty":-31.809251,"median":-13.976035,"eighty":-11.179254,"marketCap":968933450},{"date":"2025-03-07","current":-10.338636,"twenty":-31.758412,"median":-13.909847,"eighty":-11.12128,"marketCap":918298310},{"date":"2025-03-14","current":-11.556083,"twenty":-31.698577,"median":-13.789262,"eighty":-11.11355,"marketCap":1026434373},{"date":"2025-03-21","current":79.165838,"twenty":-31.423076,"median":-13.627303,"eighty":-11.045914,"marketCap":956719157},{"date":"2025-03-28","current":70.412668,"twenty":-30.971251,"median":-13.353241,"eighty":-10.90871,"marketCap":850937097},{"date":"2025-04-04","current":52.673943,"twenty":-30.878569,"median":-13.283951,"eighty":-10.748316,"marketCap":636564605},{"date":"2025-04-11","current":56.469566,"twenty":-30.809057,"median":-13.129602,"eighty":-10.622099,"marketCap":682434702},{"date":"2025-04-17","current":61.504575,"twenty":-30.778163,"median":-12.849861,"eighty":-10.560868,"marketCap":743282789},{"date":"2025-04-25","current":70.645053,"twenty":-30.585076,"median":-12.780906,"eighty":-10.377285,"marketCap":853745471},{"date":"2025-05-02","current":72.449806,"twenty":-30.310846,"median":-12.626921,"eighty":-10.338636,"marketCap":875555902},{"date":"2025-05-09","current":73.535777,"twenty":-30.136978,"median":-12.473999,"eighty":-10.164715,"marketCap":888679866},{"date":"2025-05-16","current":132.923099,"twenty":-29.947887,"median":-12.417259,"eighty":-9.938068,"marketCap":963825388},{"date":"2025-05-23","current":136.20365,"twenty":-29.754799,"median":-12.327984,"eighty":-9.652614,"marketCap":987612669},{"date":"2025-05-30","current":117.840031,"twenty":-29.349619,"median":-12.308068,"eighty":-9.440044,"marketCap":854458067},{"date":"2025-06-06","current":99.64599,"twenty":-28.753768,"median":-12.251767,"eighty":50.257139,"marketCap":722533070},{"date":"2025-06-13","current":100.896253,"twenty":-28.630129,"median":-12.168656,"eighty":56.159719,"marketCap":731598729},{"date":"2025-06-20","current":104.146938,"twenty":-27.795567,"median":-12.087508,"eighty":59.335648,"marketCap":755169444},{"date":"2025-06-27","current":92.269436,"twenty":-26.976012,"median":-11.969641,"eighty":62.92987,"marketCap":669045678}],"updateTime":1751167838765}}}